New insights to improve treatment adherence in asthma and COPD

Maureen George1
Bruce Bender2

1School of Nursing, Columbia University, New York, NY, USA; 2Division of Pediatric Behavioral Health, National Jewish Health, Denver, CO, USA

Abstract: Chronic respiratory diseases such as asthma and COPD are typically managed by daily inhaled medication. However, the efficacy of an inhaled medication depends upon a patient’s adherence to therapy, which refers to whether the medication is actually taken as prescribed. In patients with these diseases, higher adherence has been associated with better health outcomes, such as improved disease control and a reduction in severe and potentially costly exacerbations. Adherence is a multifaceted concept that includes medication-related, intentional, and unintentional reasons that patients may or may not take their medication as directed. The purpose of this integrative review is to present the individual patient factors that contribute to suboptimal adherence to inhaled therapies and the associated effects on health outcomes, while also highlighting evidence-based strategies for health care providers to improve adherence to such therapies in patients with asthma or COPD. Working closely with patients to establish a model of shared decision-making, which takes patient beliefs and preferences into account when choosing treatment options, has the potential to improve adherence and overall patient outcomes in the management of asthma and COPD.

Keywords: chronic disease, health behavior, evidence-based medicine, inhalers

Introduction

Recent advances in the understanding of the pathophysiology of asthma and COPD have led to the development of new therapies and combinations thereof to manage these chronic respiratory diseases. Health care providers who treat these patients generally follow international and national treatment guidelines as well as strategy reports that are updated more frequently to make recommendations based on the latest research. Nevertheless, the patient is responsible for following through with taking medication as prescribed.

Suboptimal adherence is defined as the failure of patients to take their medication as directed by their clinician. Higher adherence has been associated with positive health outcomes, including improved disease control and a reduction in mortality. General medicine reviews estimate that approximately 50% of medications for chronic disease are not taken as prescribed. Adherence rates tend to be even lower for patients with asthma or COPD, with estimates ranging widely from 22% to 78%. This may be due, in part, to the additional challenges of inhaled therapy, which has a central role in asthma and COPD disease management.

The terminology used in the ABC (3-step) adherence framework includes (A) initiation, (B) implementation, and (C) persistence or discontinuation. Initiation refers to whether or not the patient takes the first dose of medication. Implementation is related to the alignment between the patient’s actual dosing
and the prescribed regimen, which is a longitudinal measure of the patient’s dosing history. Persistence is the time between initiation and treatment cessation, which may or may not be the intended end of the prescription.

Considerable variability exists in the measurement of adherence. Electronic monitoring via dispensing records can determine how often prescriptions are filled, or an electronic monitoring device attached to an inhaler can be used to record the number of times the inhaler was actuated and the medication inhaled. Methods to evaluate adherence in clinical trials include patient behavioral questionnaires (eg, self-report measures like the validated Medication Adherence Report Scale for Asthma [MARS-A] and the Medication Intake Survey-Asthma [MIS-A]), dispensing records, dose or pill counting/medication possession ratios (MPRs; number of days’ supply/number of days in study), electronic inhaler monitoring, and drug assays. Adherence in asthma and COPD is most commonly measured by self-report (37.8%) and prescription refill data (32.8%), with electronic dose monitoring (19.3%) rising in popularity. However, self-report measures overall are notoriously unreliable, often overestimating adherence by as much as 50%.

This integrative review encompasses discussion of both recent studies and other reviews that were published through 2018, providing a timely update of the adherence literature for these chronic diseases. We have chosen studies published in the past 10 years that investigated the relationship between adherence and outcomes in asthma and COPD. The purpose of this manuscript is to highlight the many factors that contribute to suboptimal adherence to inhaled medication in asthma and COPD, describe the consequences for health outcomes, and present strategies supported by the literature that clinicians can employ to improve adherence to inhaled therapies and, in turn, improve patient outcomes.

Factors that contribute to suboptimal adherence

To understand the reasons for suboptimal adherence, health care providers should elicit patients’ beliefs and concerns about their disease and the medication(s) used to treat it. Factors that contribute to suboptimal adherence fall into 3 main categories (Figure 1). Medication factors include reasons that are directly related to the medication itself (eg, side effects, ease of inhaler use). For example, correct inhaler technique can be challenging for patients and is vital to optimal therapy delivery and thus a critical component in adherence. Intentional factors contributing to suboptimal adherence are the result of the patient’s choices (eg, perception that treatment is unnecessary), whereas unintentional factors are not conscious decisions made by the patient (eg, misunderstanding directions).

Incorrect inhaler technique is a manifestation of unintentional suboptimal adherence. The use of inhaled therapies adds to the complexity of the medication regimen. Patients may have difficulty using certain inhalers for a variety of reasons, including comorbidities such as arthritis or cognitive impairments. Other important aspects of the medication regimen include the use of multiple inhalers versus a single combined inhaler as well as the frequency of dose administration required each day, although available data have not shown meaningful changes in clinical outcomes with once-daily versus twice-daily dosing for inhaled therapies. Furthermore, it may be difficult to establish and sustain the correct technique when inhalers require different administration techniques. For example, dry-powder inhalers (DPIs) require rapid and forceful inspiration to properly deliver the drug, whereas this type of inhalation is not recommended for metered-dose inhalers (MDIs) and nebulizers. Furthermore, in some cases, patients may have difficulty coordinating actuation and inspiration to correctly use a pressurized MDI, whereas other patients have difficulty inhaling forcefully enough to actuate a DPI. Cognitive impairment is especially an issue in elderly patients with COPD. For patients with reduced cognitive function, DPIs have been associated with better technique than MDIs. In this context, it may be helpful for patients to have device types (ie, MDI vs DPI) that match for both controller and reliever therapy, avoiding complications that might arise from needing to distinguish and use more than 1 technique. Critical errors in inhaler technique (eg, actuation against lips, teeth, or tongue) have been shown to increase risk of hospitalization, emergency department visits, and the use of antibiotics and oral corticosteroids (OCSs). The likelihood of these errors occurring can be reduced by proper instruction and checks on inhaler technique at follow-up appointments.

Asthma and COPD are generally accepted to be 2 distinct respiratory diseases that affect differing populations and take unique developmental courses. Each disease can present its own challenges to patient adherence; 1 such factor is the age of onset. Patients with COPD tend to be older and may have comorbidities as a result of smoking that require several medications, so it is important to
consider all medications the patient is taking and any potential contraindications or potential cognitive changes that may cause difficulty with correct inhaler usage. In contrast, asthma can present at any age, and younger children with asthma may also have difficulty using inhalers correctly, especially in terms of inhalation technique. Concerns about adverse effects, such as growth suppression and osteoporosis, and particularly about the necessity of steroid treatment (inhaled or oral), may cause parents of children with asthma to be less likely to enforce adherence to prescribed therapy. Some clinicians may also be hesitant to prescribe inhaled corticosteroids (ICSs) to children for these same reasons. However, the 2018 Global Initiative for Asthma (GINA) report does recommend daily ICS therapy in children, and this course of therapy has not been shown to significantly impact final adult height when used at lower doses compared with higher doses.

Additional difficulties with adherence to inhalation therapy may occur as children with asthma age and become more independent. Adolescents with asthma have reported forgetfulness, lack of routine, social stigma around using inhalers, and lack of family support (eg, parents not accepting their asthma diagnosis) as reasons for suboptimal adherence. However, overall, increasing age has been associated with higher adherence to asthma therapy. Another important factor that distinguishes asthma from COPD is the course of the disease itself. The airflow obstruction that occurs in asthma is reversible, whereas COPD is a progressive and irreversible deterioration of lung function. Depression is a common comorbidity in asthma and COPD that undermines adherence; as a result, treatment for depression in patients with asthma or COPD is generally associated with improved adherence.

**Effects of suboptimal adherence on patient outcomes**

**Asthma**

Studies have shown that higher adherence is associated with better symptom control in patients with asthma, whereas suboptimal adherence is a modifiable independent risk factor for asthma exacerbations. However, the consequences of suboptimal adherence to asthma therapy go beyond exacerbations. For instance, suboptimal adherence can lead to reduced functional status, reduced quality of life, and increased use of healthcare resources. Therefore, strategies to improve adherence are critical to optimize outcomes for patients with asthma.

**COPD**

Similar to asthma, suboptimal adherence to COPD therapy also has significant consequences. Suboptimal adherence can lead to increased symptoms, exacerbations, and hospitalizations, as well as reduced quality of life. Moreover, suboptimal adherence can also increase the risk of complications associated with COPD, such as respiratory infections and pulmonary exacerbations. Therefore, efforts to improve adherence to COPD therapy are also crucial to optimize outcomes for patients with COPD.

**Figure 1** Factors contributing to suboptimal adherence in asthma and COPD. The factors that contribute to suboptimal adherence in asthma and COPD are grouped into 3 major categories.

**Notes:** Image: iStock.com/Alessandro2802. Data from Global initiative for asthma. http://www.ginasthma.org; Makela et al; Bryant et al and van Boven.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; HCP, health care provider.
factor for asthma exacerbations (Table 1).2,3 Specifically, high adherence (eg, MPR ≥80%) to asthma controller therapy, such as ICS, has been associated with significantly reduced risk of exacerbation, reduced OCS use, and positive impacts on asthma-related mortality.3,8,38,39 A study in pediatric patients with moderate persistent asthma showed that medication adherence was also a strong determinant of asthma control (as defined by the 2018 GINA report).2,30

Given that poor asthma control can be a result of suboptimal adherence, it is important to distinguish between a patient with asthma who is not adhering to his or her current therapy and a patient with asthma who requires progression to a higher GINA treatment step to control his or her symptoms. For these reasons, it is important to assess both adherence and inhaler technique before stepping up asthma therapy so as to avoid unnecessary medications.2 The use of electronic monitoring devices has been proposed to better identify pediatric patients with severe disease who require step-up therapy despite reportedly high adherence.40

COPD

Exacerbations resulting in hospitalization are thought to account for approximately 45% of direct medical costs associated with COPD and therefore can be expensive for the health care system.41 In fact, complex admissions requiring intensive care, intubation, or both, accounted for only 5.8% of hospital-based COPD care but 20.9% of costs in 2008.42 Higher adherence has been shown to significantly reduce moderate and severe exacerbations in COPD and also to lower mortality rates (Table 2).38,43 In contrast, suboptimal adherence has been associated with increased hospitalization and mortality, reduced quality of life, and loss of productivity.38,44 For patients with severe COPD, adherence to treatment is associated with lower health care costs and a lower risk of an intensive care unit stay.45 Adherence in combination with persistence of treatment is necessary to achieve improved clinical outcomes.44

Improving adherence to inhaled therapies in clinical practice

According to international guidelines for both asthma and COPD, it is important for clinicians to have empathetic discussions with patients to assess adherence, along with symptom control and inhaler technique, at every office visit. Suggested topics1,2 for discussions with patients who have asthma or COPD include: 1) the number of days per week the patient takes his or her inhaled medication; 2) the patient’s beliefs about his or her medication (including the perceived necessity), the cost of medications, and how often they are refilled; and 3) the importance of adherence with daily controller medications even when symptoms are infrequent. Although forgetfulness is the most often-cited reason for suboptimal adherence,46 patients may claim that they forgot in order to avoid further discussion of the true reason(s) for not taking their medication as prescribed.

Good communication by health care providers helps with increased satisfaction and better adherence, in turn improving health outcomes and reducing the use of health care resources.2,47 Assessing patients’ beliefs about their preferred treatment strategies and their prescribed medications is critical.48 For example, a recent German study showed that patients with asthma or COPD who believed their specific medications were necessary were more likely to be adherent, whereas patients with asthma who were concerned about overprescription of medication by doctors were less likely to adhere to their prescribed treatment.49

Training patients on correct inhaler technique is crucial and should be conducted routinely.25 When providing patient education about inhalers, providers should do the following: 1) know how each device works and how to optimize delivery to the lungs; 2) be able to effectively demonstrate for the patient how the device works; 3) teach the patient how to use the device with the correct technique; and 4) regularly review the patient’s technique and provide additional training as necessary.50 Educational interventions on inhaler technique are effective, and predictors of success of the intervention include low baseline performance, outpatient setting, and short follow-up time.51 A number of studies have shown that 1-on-1 educational counseling by pharmacists about correct inhaler technique, as well as the importance of adherence, smoking cessation, exercise, and follow-up, not only increases adherence in patients with COPD52 but can also reduce severe exacerbations and hospitalization rates.53 One study also showed that home visits by trained asthma educators increased adherence and decreased emergency department visits, but the improvements in outcomes were inconsistent and not long-lasting.54 In contrast, a school nurse-supervised asthma program, in which pediatric patients with persistent asthma and suboptimal adherence received nurse-supervised daily ICS therapy at school, decreased asthma-related emergency department visits, reduced asthma-related hospital admissions, and lowered asthma reliever medication refills over 1 year.55
Table 1 Summary of study results linking inhaled medication adherence to patient outcomes in asthma

| Study       | Population | Study design | Measure(s) of adherence | Outcomes                                                                 |
|-------------|------------|--------------|-------------------------|--------------------------------------------------------------------------|
| Bender 2010 | US patients aged 18–65 years | Randomized clinical trial | Electronic dose counter ● Changes in canister weight (budesonide/formoterol only) | IVR significantly improved adherence by 32% (P=0.003) ● BMQ showed a greater upward shift in medication beliefs for the IVR group (P=0.007) ● No difference observed in AQLQ or ACT between groups |
| Melani 2011 | Italian patients aged ≥14 years | Cross-sectional, observational study of patients using an inhaler regularly at home | Investigator-observed placebo inhaler use | Suboptimal inhaler technique increased risk of hospitalization (47%, P=0.001) and the use of the ER (62%, P=0.0006), antibiotics (50%, P=0.00004), and OCSs (54%, P=0.00003) |
| Petrie 2012 | New Zealander patients aged 16–45 years | Randomized clinical trial | Patient-reported | Average adherence over time was significantly higher in the intervention group (57.8%) than the control group (43.2%, P=0.003) ● Patients with an average adherence ≥80% included significantly more patients from the intervention group (25.9%) compared with the control group (10.6%, P=0.034) ● Perceptions of controller medication necessity, long-term nature of asthma, and asthma control were all positively increased in the intervention group relative to the control group (all P<0.05) |
| Vollmer 2013 | US patients aged ≥18 years | Pragmatic clinical trial | mMPR ≥0.8 | Primary analysis: IVR significantly increased adherence by 0.02 (P=0.002) compared with usual care ● Post hoc analysis (receiving ≥2 IVR contacts): adherence increased by 0.06 (P<0.001) ● No difference observed in asthma morbidity (SABA use or urgent asthma health care use) |
| Ismaila 2014 | Canadian patients aged ≥12 years | Observational study of patients taking FSC | ● MPR ≥80% ● Persistence: ≤30-day treatment gap | MPR ≥80% reduced exacerbation risk by 52% (P<0.001) ● Persistence reduced exacerbation risk by 58% (P<0.001) |
| Makinova 2015 | US patients aged 5–63 years | Retrospective claims database study of patients taking any asthma controller medication | PDC ≥50% | Adherent patients were 96.7% more likely to have ≥6 SABA prescription claims (P<0.001) ● Adherent patients had 0.11 fewer OCS prescription claims (P<0.001) |
| Jentzsch 2017 | Brazilian patients aged 5–16 years | Prospective, observational study of patients with uncontrolled moderate, persistent asthma despite high adherence | Electronic dose counter | Patients with controlled asthma had significantly higher adherence rates at 2, 4, and 6 months (87.8%, 74.9%, and 62.1%, respectively) compared with uncontrolled patients (71.7%, 56.0%, and 47.6%, P=0.000, P=0.000, P=0.002, respectively) |
| Trivedi 2017 | US patients in grades 1–12; mean age of 10.5 years | Retrospective study of children with persistent asthma | Daily school nurse-supervised ICS therapy | Asthma-related ER visits decreased 37.5% (P=0.001), asthma-related hospital admissions decreased from a mean of 0.3 to 0 (P<0.001), and the number of reliever medication refills decreased by 46.3% (P<0.001) compared with pre-intervention |

(Continued)
A multidisciplinary approach to patient care supports the patient in the management of both mental and physical aspects of their disease. The inclusion of psychologists on such teams can, therefore, improve self-management by eliciting changes in behavior. Adherence can also be improved by implementing a shared decision-making process regarding medication and dose regimen choices between health care provider and patient. Shared decision-making is an approach whereby patients and health care providers make joint health care decisions based upon the best available evidence regarding possible risks and benefits associated with viable options yet still anchored to patient preferences and values. It is also important to consider the health literacy of the patient when developing

Table 1  (Continued).

| Study         | Population                  | Study design                        | Measure(s) of adherence | Outcomes                                                                 |
|---------------|-----------------------------|-------------------------------------|-------------------------|--------------------------------------------------------------------------|
| Jochmann      | UK patients aged 5–17 years | Prospective, observational study to distinguish between severe disease and suboptimal adherence | Electronic dose counter | • 4 groups were identified based on adherence and asthma control; 24% had high adherence and improved control, 18% had suboptimal control despite high adherence, 26% had good control despite suboptimal adherence, and 32% had suboptimal control and suboptimal adherence |

Abbreviations: AQLQ, asthma quality of life questionnaire; ACT, asthma control test; BMQ, belief in medications questionnaire; ER, emergency room; FSC, fluticasone propionate/salmeterol combination; ICS, inhaled corticosteroid; IVR, interactive voice recognition; mMPR, modified medication possession ratio; MPR, medication possession ratio; OCS, oral corticosteroid; PDC, proportion of days covered; SABA, short-acting beta-agonist.

Table 2  Summary of study results linking inhaled medication adherence to patient outcomes in COPD

| Study          | Population                  | Study design                        | Measure of adherence | Outcome(s)                                                                 |
|----------------|-----------------------------|-------------------------------------|----------------------|---------------------------------------------------------------------------|
| Vestbo         | TORCH cohort, aged 40–80 years | Subanalysis of TORCH patient database | Electronic dose counter | • High adherence was associated with 60% decreased risk of death (P<0.001) over the 3-year study period |
| Ismaila        | Canadian patients aged ≥40 years | Observational claims database study | • MPR ≥80%          | • Tiotropium MPR ≥80% decreased the rate of both moderate (–0.65*) and severe (–0.2*) exacerbations (P<0.001 for both) |
| Tommelein      | PHARMACOP cohort, aged ≥50 years | Randomized, controlled, parallel-group trial | MRA ≥80%            | • Severe exacerbation rate decreased by 55% (P=0.007) after medication counseling by a pharmacist |
| Kim            | South Korean high-grade COPD patients aged ≥40 years | Observational claims database study | • MPR ≥80%          | • Adherent patients had 10.4% lower all-cause health care costs (P=0.0003), 11.7% lower COPD-related health care costs (P<0.0001), and were less likely to require ICU treatment (OR 0.74, [95% CI 0.60–0.91]) |

Note: *Mean number of events/patient/100 days during the follow-up period. Abbreviations: CI, confidence interval; FSC, fluticasone propionate/salmeterol combination; ICU, intensive care unit; MPR, medication possession ratio; MRA, medication refill adherence; OR, odds ratio.
education and treatment action plans, so these plans can be delivered at the appropriate level to support adherence to therapy.

Electronic devices that track adherence have been available for over 3 decades, but new adherence-intervention smart technology includes a growing number of potential uses for asthma patients, such as feedback on inhaler technique, portable fractional exhaled nitric oxide measurement devices, and GPS devices with alerts about environmental contaminants that could worsen symptoms. Such technology has the potential to remotely track disease variables and remind patients to take their medication, avoid triggers, or contact their physician when symptoms worsen. A review of patient-reminder systems that are meant to combat forgetfulness in taking medications found an increase in adherence of up to 22% but no effect on outcomes or quality of life, whereas education tailored to patients’ illness and medication beliefs significantly improved adherence in adolescents and adults. A study investigating the use of a monitor attached to patients’ inhalers showed that patients with asthma who received medication reminders and feedback from such a device had significantly higher adherence than the control group who did not receive feedback or reminders. Another study used an electronic monitoring device in patients with COPD to track the quality and timing of inhaler use to improve adherence in distinct clusters of patients (regular use, frequent technique errors; irregular use, good technique; and irregular use, frequent technique errors). One recently completed trial (NCT02864342) showed that electronic medication reminders improved adherence to inhaled medication in patients with COPD. The majority of patients indicated that they found the device with accompanying smartphone application easy to use and the reminders helped to ensure their medication was taken as prescribed. Additional studies in progress are investigating electronic means of increasing adherence to inhalation therapies, but electronic interventions also raise a number of potential ethical questions related to patient privacy. Furthermore, the real-world feasibility of shared decision-making, in which providers deliver a brief, 7-minute intervention during a regular office visit, is currently being explored. An assessment of the effects of this decision process on patient adherence to ICS therapy is one of the secondary outcomes being measured in this study.

In COPD, multifaceted interventions have been shown to have the greatest impact on improved medication adherence, although not all studies have shown a positive effect. For example, pulmonary rehabilitation is a comprehensive intervention to promote long-term adherence to health-enhancing behaviors in patients with COPD, but the specific effects on medication adherence are not well studied. However, individually tailored care plans, educational sessions about the illness and inhaler technique, health care provider visits, and/or weekly phone calls do improve adherence. Figure 2 illustrates how these different types of interventions can fit together in a patient’s overall care plan to improve medication adherence.

Conclusions

Although inhaled maintenance therapy is vital for many patients with asthma or COPD, suboptimal adherence is frequently an issue, and the underlying causes of it are multifactorial and complex. Suboptimal adherence is associated with negative consequences related to disease control, mortality, and health care resource use; it is, therefore, important to optimize each patient’s therapy to improve adherence and maximize the therapeutic effects of prescribed medications. Therapy optimizations may include routine inhaler technique training or changing to a different type of inhaler that is easier for the patient to use.
correctly. Shared decision-making allows for collaboration between patient and physician to develop a treatment plan that addresses barriers to adherence and fosters an environment that is favorable to patient education, communication, and counseling.

**Abbreviation list**

COPD, chronic obstructive pulmonary disease; GINA, Global Initiative for Asthma; GPS, global positioning system; ICS, inhaled corticosteroid; MARS-A, Medication Adherence Report Scale for Asthma; MIS-A, Medication Intake Survey-Asthma; MPR, medication possession ratio; OCS, oral corticosteroid.

**Acknowledgments**

Medical writing support was provided by Shane Walton, PhD, of MedErgy (Yardley, PA, USA), under the direction of the authors, in accordance with Good Publication Practice (GPP3) guidelines, and was funded by AstraZeneca (Wilmington, DE, USA).

**Author contributions**

Both authors were involved in the analysis and interpretation of the literature search results. Both authors participated in the development and critical review of the manuscript, provided final approval to submit for publication, and agree to be accountable for all aspects of the work.

**Disclosure**

MG has served as a consultant for AstraZeneca and Teva. MG also reports personal fees from Teva and AstraZeneca, outside the submitted work. The authors report no other conflicts of interest in this work.

**References**

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018 Report); 2018. Available from: http://goldcopd.org. Accessed May 24, 2018.

2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention; 2018. Available from: http://www.ginasthma.org. Accessed February 8, 2019.

3. Makela MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107(10):1481–1490. doi:10.1016/j.resmed.2013.04.005

4. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557):15. doi:10.1136/bmj.38875.675486.55

5. Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med. 2012;157(11):785–795. doi:10.7326/0003-4819-157-11-201212040-00538

6. DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42(3):200–209.

7. Bryant J, McDonald VM, Boyes A, Sanson-Fisher R, Paul C, Melville J. Improving medication adherence in chronic obstructive pulmonary disease: a systematic review. Respir Res. 2013;14:109. doi:10.1186/1465-9921-14-19

8. Barnes CB, Ullric CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care. 2015;60(3):455–468. doi:10.4187/rescare.03200

9. Vijens B, Dima AL, Van Ganse E, et al. What we mean when we talk about adherence in respiratory medicine. J Allergy Clin Immunol Pract. 2016;4(5):802–812. doi:10.1016/j.jaip.2016.05.019

10. Kikidis D, Konstantinos V, Tzovaras D, Usmani OS. The digital asthma patient: the history and future of inhaler based health monitoring devices. J Aerosol Med Pulm Drug Deliv. 2016;29(3):219–232. doi:10.1089/jamp.2015.1267

11. PROAIR® DIGITALERTM (Albuterol Sulfate) [Packet Insert]. Frazer, PA: Teva Respiratory, LLC; December 2018.

12. Clatworthy J, Price D, Ryan D, Haughney J, Rome R. The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Prim Care Respir J. 2009;18(4):300–305. doi:10.4104/pcrj.2009.00037

13. Cohen JL, Mann DM, Wisnivesky JP, et al. Assessing the validity of self-reported medication adherence among inner-city asthmatic adults: the Medication Adherence Report Scale for Asthma. Ann Allergy Asthma Immunol. 2009;103(4):325–331.

14. Dima AL, van Ganse E, Laforest L, Texier N, de Bruin M, The Astro-Lab Group. Measuring medication adherence in asthma: development of a novel self-report tool. Psychol Health. 2017;32(10):1288–1307. doi:10.1080/08870446.2017.1290248

15. Bender BG. Nonadherence to asthma treatment: getting unstuck. J Allergy Clin Immunol Pract. 2016;4(5):849–851. doi:10.1016/j.jaip.2016.07.007

16. DePietro M, Gilbert I, Millette LA, Kiebe M. Inhalation device options for the management of chronic obstructive pulmonary disease. Postgrad Med. 2018;130(3):83–97. doi:10.1080/00325481.2018.1399042

17. Mokoca MC, Lombard L, MacHale EM, et al. In patients with severe uncontrolled asthma, does knowledge of adherence and inhaler technique using electronic monitoring improve clinical decision making? A protocol for a randomised controlled trial. BMJ Open. 2017;7(6):e015367. doi:10.1136/bmjopen-2016-015367

18. van Boven JF, Trappenburg JC, van der Molen T, Chavannes NH. Towards tailored and targeted adherence assessment to optimise asthma management. NPJ Prim Care Respir Med. 2015;25:15046. doi:10.1038npjpcr.2015.46

19. Sanduzzi A, Balbo P, Candoli P, et al. COPD: adherence to therapy. Multidis Respir Med. 2014;9(1):60. doi:10.1186/2049-6958-9-60

20. Perez de Llano L, Sanmartin AP, Gonzalez-Barcala FJ, et al. Assessing adherence to inhaled medication in asthma: impact of once-daily versus twice-daily dosing frequency. The ATAUAD study. J Asthma. 2018;55(9):933–938. doi:10.1080/02770903.2018.1426709

21. Ibrahim M, Verna R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Med Devices (Auckl). 2015;8:131–139. doi:10.2147/MDER.S48838

22. Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018;19(1):10. doi:10.1186/s12931-017-0710-y
23. Baird C, Lovell J, Johnson M, Shiel K, Ibrahim JE. The impact of cognitive impairment on self-management in chronic obstructive pulmonary disease: a systematic review. Respir Med. 2017;129:130–139. doi:10.1016/j.rmed.2017.06.006

24. Kaplan A, Price D. Matching inhaler devices with patients: the role of the primary care physician. Can Respir J. 2018;25(4):246–250. doi:10.1016/j.jdcm.2017.09.003

25. Melani AS, Bonavita M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–938. doi:10.1016/j.rmed.2011.01.005

26. Sears MR. Predicting asthma outcomes. J Allergy Clin Immunol. 2015;136(4):829–836; quiz 837. doi:10.1016/j.jaci.2014.04.048

27. The Inhaler Error Steering Committee, Price D, Bosnic-Anticevich S, et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med. 2013;107(1):37–46. doi:10.1016/j.rmed.2012.09.017

28. Philip J. The effects of inhaled corticosteroids on growth in children. Open Respir Med J. 2014;8:66–73. doi:10.2174/187430601408106006

29. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354(19):1985–1997. doi:10.1056/NEJMoa051378

30. Jentzsch NS, Silva GCG, Mendes GMS, Brand PLP, Camargos P. Treatment adherence and level of control in moderate persistent asthma in children and adolescents treated with fluticasone and salmeterol. J Pediatr (Rio J). 2017;95(1):69–75. doi:10.1016/j.jped.2017.10.008

31. Bender BG, Bender SE. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin North Am. 2009;29(4):675–693. doi:10.1016/j.iac.2009.09.003

32. Siemens A, Dyer R, Fleming L, Bush A, Griffiths C. What do adolescents with asthma really think about adherence to inhalers? Insights from a qualitative analysis of a UK online forum. BMJ Open. 2017;7(6):e015245. doi:10.1136/bmjopen-2016-015245

33. Potier KJ, Perry K, Broadbent E, Weinman J. A text message programme designed to modify patients’ illness and treatment beliefs improves self-reported adherence to asthma preventer medication. Br J Health Psychol. 2012;17(1):74–84. doi:10.1111/j.2044-8287.2011.02071.x

34. Wei YJ, Simoni-Wastila L, Albrecht JS, et al. The association of antidepressant treatment with COPD medication adherence: responses to interviews, focus groups, and questionnaire. Clin Ther. 2014;36(4):1417–1425. doi:10.1016/j.clinthera.2014.09.003

35. Thomas M, Aronson KJ, Leach CJ, et al. The association of adherence to inhaled corticosteroids: an essential tool in identifying severe asthma in children. Eur Respir J. 2017;50(6). doi:10.1183/13993003.0071-2017

36. Wei YJ, Albrecht JS, Simoni-Wastila L,et al. The association of antidepressant treatment with COPD medication adherence: responses to interviews, focus groups, and questionnaire. Clin Ther. 2014;36(4):1417–1425. doi:10.1016/j.clinthera.2014.09.003

37. Thomas M, Aronson KJ, Leach CJ, et al. The association of adherence to inhaled corticosteroids: an essential tool in identifying severe asthma in children. Eur Respir J. 2017;50(6). doi:10.1183/13993003.0071-2017

38. Thomas M, Aronson KJ, Leach CJ, et al. The association of adherence to inhaled corticosteroids: an essential tool in identifying severe asthma in children. Eur Respir J. 2017;50(6). doi:10.1183/13993003.0071-2017

39. Mapel D, Roberts MH, Blanchette CM, Petersen H, Ramachandran S. Effectiveness of inhaled combined corticosteroid/long-acting bronchodilator treatment in reducing COPD exacerbations and short-acting bronchodilator use. JCOIM. 2013;20(2):60–68.

40. Dalal AA, Shah M, D’Souza AO, Rane P. Costs of COPD exacerbations in the emergency department and inpatient setting. Respir Med. 2011;105(3):455–460. doi:10.1016/j.rmed.2010.09.003

41. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64(11):939–943. doi:10.1136/thx.2009.113662

42. van Boven JF, Chavannes NH, van der Molen T, Rutten-van Molken MP, Postma MJ, Veeger S. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir Med. 2014;108(1):103–113. doi:10.1016/j.rmed.2013.08.014

43. Kim JA, Lim MK, Kim K, Park J, Rhee CK. Adherence to inhaled medications and its effect on healthcare utilization and costs among high-grade chronic obstructive pulmonary disease patients. Clin Drug Investig. 2018;38(4):333–340. doi:10.1007/s40261-017-0612-2

44. Iuga AO, McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy. 2014;7:35–44. doi:10.2147/RMHP.S19801

45. Clark NM, Cabana MD, Nan B, et al. The clinician-patient-partnership paradigm: outcomes associated with physician communication behavior. Clin Pediatr (Phila). 2008;47(1):49–57. doi:10.1177/0187832907305560

46. George M. Health beliefs, treatment preferences and complementary and alternative medicine for asthma, smoking and lung cancer self-management in diverse Black communities. Patient Educ Couns. 2012;89(3):489–500. doi:10.1016/j.pec.2012.05.003

47. Brandstetter S, Finger T, Fischer W, et al. Differences in medication adherence are associated with beliefs about medicines in asthma and COPD. Clin Transl Allergy. 2017;7:39. doi:10.1186/s13610-017-0175-6

48. Scullion J. The nurse practitioners’ perspective on inhaler education in asthma and chronic obstructive pulmonary disease. Can Respir J. 2018;25:252519. doi:10.11581/2018/252519

49. Klijn SL, Hiligsmann M, Evers S, Roman-Rodriguez M, van der Molen T, van Boven JFM. Effectiveness and success factors of educational inhaler technique interventions in asthma & COPD patients: a systematic review. NPJ Prim Care Respir Med. 2017;27(1):24. doi:10.1038/s41533-017-0022-1

50. Abdulsalim S, Unnikrishnan MK, Manu MK, Alrasheedy AA, Godman B, Morisky DE.Structured pharmacist-led intervention programme to improve medication adherence in COPD patients: a randomized controlled study. Res Social Adm Pharm. 2018;14(10):909–914. doi:10.1016/j.sapharm.2017.10.008

51. Tommelein E, Mehues Y, Van Hees T, et al. Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial. Br J Clin Pharmacol. 2014;77(5):756–766. doi:10.1111/bcp.12242

52. Osuki M, Eakin MN, Rand CS, et al. Adherence feedback to improve asthma outcomes among inner-city children: a randomized trial. Pediatrics. 2009;124(6):1513–1521. doi:10.1542/peds.2008-2961

53. Trivedi M, Patel J, Lessard D, et al. School nurse asthma program reduces healthcare utilization in children with persistent asthma. J Asthma. 2018;55(10):1131–1137. doi:10.1080/02770903.2017.1396473

54. Bender BG, Apter A, Bogen DK, et al. Test of an interactive voice response intervention to improve adherence to controller medications in adults with asthma. J Am Board Fam Med. 2010;23(2):159–165. doi:10.3122/jabfm.2010.02.090112

55. Vollmer WM, Feldstein A, Smith DH, et al. Use of health information technology to improve medication adherence. Am J Manag Care. 2011;17(12Spec No.):SP79–87.

56. Lunn S, Restrick L, Stern M. Managing respiratory disease: the role of a psychologist within the multidisciplinary team. Chron Respir Dis. 2017;14(1):45–53. doi:10.1177/1479972316688914
59. Wilson SR, Strub P, Buist AS, et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. *Am J Respir Crit Care Med*. 2010;181(6):566–577. doi:10.1164/rccm.200906-0907OC

60. Blaiss MS, Steven GC, Bender B, Bukstein DA, Meltzer EO, Winders T. Shared decision making for the allergist. *Ann Allergy Asthma Immunol*. 2019;122(5):463–470. doi:10.1016/j.anai.2018.08.019

61. Bender BG. Technology interventions for nonadherence: new approaches to an old problem. *J Allergy Clin Immunol Pract*. 2018;6(3):794–800. doi:10.1016/j.jaip.2017.10.029

62. Tran N, Coffman JM, Sumino K, Cabana MD. Patient reminder systems and asthma medication adherence: a systematic review. *J Asthma*. 2014;51(5):536–543. doi:10.3109/02770903.2014.888572

63. Foster JM, Usherwood T, Smith L, et al. Inhaler reminders improve adherence with controller treatment in primary care patients with asthma. *J Allergy Clin Immunol*. 2014;134(6):1260–1268 e3. doi:10.1016/j.jaci.2014.05.041

64. van Boven JFM, Cushen B, Sulaiman I, et al. Personalising adherence-enhancing interventions using a smart inhaler in patients with COPD: an exploratory cost-effectiveness analysis. *NPJ Prim Care Respir Med*. 2018;28(1):24. doi:10.1038/s41533-018-0092-8

65. Criner GJ, Cole T, Hahn K, Kastango K, Eudicone J, Gilbert I. Late breaking abstract - a randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients. *Eur Respir J*. 2018;52(Suppl 62):PA1988. doi:10.1183/13993003.01675-2018

66. Campbell JI, Eyal N, Musiimenta A, Haberer JE. Ethical questions in medical electronic adherence monitoring. *J Gen Intern Med*. 2016;31(3):338–342. doi:10.1007/s11606-015-3502-4

67. George M, Puntalov M, Sommers MLS, et al. Shared decision-making in the BREATHE asthma intervention trial: a research protocol. *J Adv Nurs*. 2019;75(4):876–887. doi:10.1111/jan.13916

68. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. *Am J Respir Crit Care Med*. 2013;188(8):e13–e64. doi:10.1164/rccm.201309-1634ST

69. Leiva-Fernandez J, Leiva-Fernandez F, Garcia-Ruiz A, Prados-Torres D, Barnestein-Fonseca P. Efficacy of a multifactorial intervention on therapeutic adherence in patients with chronic obstructive pulmonary disease (COPD): a randomized controlled trial. *BMC Pulm Med*. 2014;14:70. doi:10.1186/1471-2466-14-70

70. Chan AH, Stewart AW, Harrison J, Camargo CA, Black PN, Mitchell EA. The effect of an electronic monitoring device with audiovisual reminder function on adherence to inhaled corticosteroids and school attendance in children with asthma: a randomised controlled trial. *Lancet Respir Med*. 2015;3(3):210–219. doi:10.1016/S2213-2600(15)00008-9